Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.
BACKGROUND:The clinical determinants of fibrosis progression in nonalcoholic fatty liver disease (NAFLD) are still under definition. AIM:To assess the clinical determinants of fibrosis progression rate (FPR) in NAFLD patients with baseline and follow-up histological evaluation, with a special focus...
Main Authors: | Serena Pelusi, Salvatore Petta, Chiara Rosso, Vittorio Borroni, Anna Ludovica Fracanzani, Paola Dongiovanni, Antonio Craxi, Elisabetta Bugianesi, Silvia Fargion, Luca Valenti |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5029872?pdf=render |
Similar Items
-
The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease.
by: Luca Valenti, et al.
Published: (2012-01-01) -
Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic fatty liver disease.
by: Edoardo Alessandro Pulixi, et al.
Published: (2014-01-01) -
Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
by: Marica Meroni, et al.
Published: (2022-03-01) -
Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease
by: Angelo Armandi, et al.
Published: (2021-03-01) -
Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease.
by: Anna Ludovica Fracanzani, et al.
Published: (2016-01-01)